On December 9, 2020, Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) closed the transaction. The company issued 15,206,372 shares at a price of CNY 22.76 for gross proceeds of CNY 419,999,994.64. The proceeds of CNY 15,206,372.00 is included in the paid-in share capital, and CNY 392,733,994.01 is included in the capital reserve (share premium).The company paid issuance expenses of CNY 12,059,628.62 including underwriting fee of CNY 6,603,773.58, CNY 801,886.79 for audit and verification fee, CNY 4,339,622.64 for legal fees, CNY 314,345.62 for statutory information disclosure fees, share registration fees and materials after printing fee. The transaction included participation from Taikang Asset Management Co., Ltd. for CNY 29,999,987.78, Perseverance Asset Management L.L.P. for CNY 26,150,450.28, GF Fund Management Co., Ltd. for CNY 29,999,739,200, China International Fund Management Company Limited for CNY 41,699,847.4, Lombarda China Fund Management Co., Ltd. for CNY 29,999,987.78, China Industrial Securities Global Fund Management Co., Ltd. for CNY 46,149,843.7, Huatai Asset Management Co., Ltd. for CNY 29,999,987.78, Xie Jinkun for CNY 42,999,976.04, Shenzhen Xinran Investment Management Co., Ltd. for CNY 32,999,989.32, Caitong Fund Management Co., Ltd. for CNY 29,999,960.16, Zheng Zhiguo for CNY 80,000,004.24.